Log in to your Inderes Free account to see all free content on this page.

Eurocine Vaccines

Be the first to follow this company

Eurocine Vaccines operates in the pharmaceutical industry with a focus on developing vaccines for the global market. The company develops vaccine candidates from early innovation and licenses them to partners for further development and commercialization. The activities are carried out in the bioscience cluster at Karolinska Institutet in Solna, Sweden.

ShowingAll content types

Press release10/7/2024, 6:15 AM

Nidhogg Resources Holding AB: Nidhogg Resources Holding: Determination of Subscription Price for TO 6

Eurocine Vaccines

Regulatory press release10/7/2024, 6:00 AM

Nidhogg Resources Holding AB: Nidhogg Resources Holding Makes Preliminary Valuation of the Vintjärn-Kölen Area

Eurocine Vaccines

Press release9/30/2024, 8:37 PM

Nidhogg Resources Holding AB: Nidhogg Resources Holding meets with the County Administrative Board of Dalarna and Falun Municipality as part of its trial mining plans in Vintjärn

Eurocine Vaccines

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release9/26/2024, 12:45 PM

Nidhogg Resources Holding AB: Nidhogg Resources Holding secures utilization of TO6 warrants for SEK 5 million, cancels negotiations regarding the acquisition of approximately 85.18 percent of the shares in Holmasjön

Eurocine Vaccines

Press release9/17/2024, 6:50 AM

Nidhogg Resources Holding AB and GreenIron Sign a Memorandum of Understanding for Fossil-Free Metal Processing

Eurocine Vaccines

Press release9/10/2024, 1:58 AM

Nidhogg Resources Holding AB: Nidhogg Resources Plans a Geophysical Survey to Investigate the Extent of Anomalies Between Vintjärn and Kölen

Eurocine Vaccines

Press release8/7/2024, 6:30 AM

Nidhogg Resources Holding AB (publ) submits consultation material as part of the plan for trial mining at the Vintjärn mine and increases ownership by 10% in Big Rock Mineral AB

Eurocine Vaccines

Regulatory press release7/31/2024, 6:55 AM

Nidhogg Resources Holding AB: Nidhogg Resources Holding secures the utilization of TO6 warrants at 100% with a conditional agreement; entered into a Letter of Intent regarding the acquisition of 85.18% of the shares in Holmasjön

Eurocine Vaccines

Press release7/19/2024, 1:52 PM

Nidhogg Resources Holding AB (publ) submits ore from Vintjärn to analyze a fossil-free beneficiation technology for metal extraction.

Eurocine Vaccines

Regulatory press release11/28/2023, 9:41 AM

Correction - Eurocine Vaccines discloses interim report for July - September 2023

Eurocine Vaccines

Regulatory press release11/28/2023, 8:04 AM

Eurocine Vaccines discloses interim report for Juli - September 2023

Eurocine Vaccines

Regulatory press release5/24/2023, 6:00 AM

Eurocine Vaccines discloses interim report for July 2022 - March 2023

Eurocine Vaccines

Regulatory press release2/28/2023, 7:15 AM

Eurocine Vaccines discloses half-year report for July - December 2022

Eurocine Vaccines

Regulatory press release1/17/2023, 8:26 PM

Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia

Eurocine Vaccines

Regulatory press release8/25/2022, 6:00 AM

Eurocine Vaccines discloses year-end report for the fiscal year 2021/2022

Eurocine Vaccines

Regulatory press release7/28/2022, 10:50 AM

Disclosure notice in Eurocine Vaccines

Eurocine Vaccines

Regulatory press release6/14/2022, 2:26 PM

Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate

Eurocine Vaccines

Regulatory press release5/20/2022, 6:15 AM

Eurocine Vaccines publishes interim report for July 2021 - March 2022

Eurocine Vaccines

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.